Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IXTEND: A Randomized Phase 2 Study to Evaluate the Combination of Ixabepilone Plus Capecitabine or Capecitabine Plus Docetaxel in the Treatment of Metastatic Breast Cancer

NCT00546364 is registered in ClinicalTrials.gov with R-Pharm as lead sponsor.

NCT NCT00546364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00546364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IXTEND: A Randomized Phase 2 Study to Evaluate the Combination of Ixabepilone Plus Capecitabine or Capecitabine Plus Docetaxel in the Treatment of Metastatic Breast Cancer
Lead sponsor
R-Pharm
Phase
Phase 2
Overall status
Terminated
Start date
February 29, 2008
Completion date
March 31, 2010
Enrollment
62 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms